Sanborn T A, Sleeper L A, Bates E R, Jacobs A K, Boland J, French J K, Dens J, Dzavik V, Palmeri S T, Webb J G, Goldberger M, Hochman J S
New York Presbyterian Hospital, Weill Medical College of Cornell University, New York, USA.
J Am Coll Cardiol. 2000 Sep;36(3 Suppl A):1123-9. doi: 10.1016/s0735-1097(00)00875-5.
We sought to investigate the potential benefit of thrombolytic therapy (TT) and intra-aortic balloon pump counterpulsation (IABP) on in-hospital mortality rates of patients enrolled in a prospective, multi-center Registry of acute myocardial infarction (MI) complicated by cardiogenic shock (CS).
Retrospective studies suggest that patients suffering from CS due to MI have lower in-hospital mortality rates when IABP support is added to TT. This hypothesis has not heretofore been examined prospectively in a study devoted to CS.
Of 1,190 patients enrolled at 36 participating centers, 884 patients had CS due to predominant left ventricular (LV) failure. Excluding 26 patients with IABP placed prior to shock onset and 2 patients with incomplete data, 856 patients were evaluated regarding TT and IABP utilization. Treatments, selected by local physicians, fell into four categories: no TT, no IABP (33%; n = 285); IABP only (33%; n = 279); TT only (15%; n = 132); and TT and IABP (19%; n = 160).
Patients in CS treated with TT had a lower in-hospital mortality than those who did not receive TT (54% vs. 64%, p = 0.005), and those selected for IABP had a lower in-hospital mortality than those who did not receive IABP (50% vs. 72%, p < 0.0001). Furthermore, there was a significant difference in in-hospital mortality among the four treatment groups: TT + IABP (47%), IABP only (52%), TT only (63%), no TT, no IABP (77%) (p < 0.0001). Patients receiving early IABP (< or = 6 h after thrombolytic therapy, n = 72) had in-hospital mortality similar to those with late IABP (53% vs. 41%, n = 64, respectively, p = 0.172). Revascularization rates differed among the four groups: no TT, no IABP (18%); IABP only (70%); TT only (20%); TT and IABP (68%, p < 0.0001); this influenced in-hospital mortality significantly (39% with revascularization vs. 78% without revascularization, p < 0.0001).
Treatment of patients in cardiogenic shock due to predominant LV failure with TT, IABP and revascularization by PTCA/CABG was associated with lower in-hospital mortality rates than standard medical therapy in this Registry. For hospitals without revascularization capability, a strategy of early TT and IABP followed by immediate transfer for PTCA or CABG may be appropriate. However, selection bias is evident and further investigation is required.
我们试图研究溶栓治疗(TT)和主动脉内球囊反搏(IABP)对纳入前瞻性、多中心急性心肌梗死(MI)合并心源性休克(CS)注册研究患者院内死亡率的潜在益处。
回顾性研究表明,因MI导致CS的患者在TT基础上加用IABP支持时院内死亡率较低。此前尚未在一项专门针对CS的研究中对这一假设进行前瞻性研究。
在36个参与中心登记的1190例患者中,884例因主要左心室(LV)衰竭导致CS。排除26例在休克发作前已置入IABP的患者和2例数据不完整的患者,对856例患者的TT和IABP使用情况进行评估。由当地医生选择的治疗方法分为四类:未进行TT,未使用IABP(33%;n = 285);仅使用IABP(33%;n = 279);仅进行TT(15%;n = 132);TT和IABP(19%;n = 160)。
接受TT治疗的CS患者院内死亡率低于未接受TT治疗的患者(54%对64%,p = 0.005),选择IABP治疗的患者院内死亡率低于未接受IABP治疗的患者(50%对72%,p < 0.0001)。此外,四个治疗组的院内死亡率存在显著差异:TT + IABP(47%),仅IABP(52%),仅TT(63%),未进行TT,未使用IABP(77%)(p < 0.0001)。接受早期IABP(溶栓治疗后≤6小时,n = 72)的患者院内死亡率与接受晚期IABP的患者相似(分别为53%对41%,n = 64,p = 0.172)。四组的血运重建率不同:未进行TT,未使用IABP(18%);仅IABP(70%);仅TT(20%);TT和IABP(68%,p < 0.0001);这对院内死亡率有显著影响(血运重建患者为39%,未进行血运重建患者为78%,p < 0.0001)。
在本注册研究中,对因主要LV衰竭导致心源性休克的患者采用TT、IABP以及通过PTCA/CABG进行血运重建治疗,与标准药物治疗相比,院内死亡率更低。对于没有血运重建能力的医院,早期TT和IABP随后立即转诊进行PTCA或CABG的策略可能是合适的。然而,选择偏倚明显,需要进一步研究。